SWS Partners’s AstraZeneca AZN Stock Holding History

SWS Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-214	Closed	-$15K	–	377
2017 Q4	$15K	Buy	+214	New	+$14.4K	0.01%	242

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

SWS Partners's AZN Position: Q1 2018 in Review

SWS Partners sold out of AstraZeneca (AZN) in Q1 2018, closing a stake of 214 shares — an estimated $15K sold.

SWS Partners first reported a position in AZN in Q4 2017 and held it in 1 quarter. The position peaked at $15K in Q4 2017. 519 funds tracked by Wall St. Rank hold AZN as of Q1 2018.

SWS Partners reported no remaining AstraZeneca position as of Q1 2018 after selling out during the quarter.
SWS Partners sold 214 AstraZeneca shares in Q1 2018, an estimated $15K.
SWS Partners first reported a position in AstraZeneca in Q4 2017 and held it in 1 quarter.
SWS Partners's AstraZeneca position peaked at $15K in Q4 2017.
519 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2018.

Based on SWS Partners's 13F filing for Q1 2018, filed 15 May 2018.